Fortimedix Surgical, a Nuth, The Netherlands-based a medical device company focused on minimally invasive surgery, completed an €11M Series A funding round.
The round was led by Chemelot Ventures, with participation from existing shareholders MKB Leningenfonds and Rijksdienst voor Ondernemend Nederland, a part of the Dutch Ministry of Economic Affairs.
The company will use these funds to support the U.S. and European commercial launch of FMX314,
Led by Mr. Wout Bijker, CEO, Fortimedix Surgical develops a single-port surgery solution that is compatible with a standard 15mm trocar for use in minimally invasive abdominal laparoscopic surgeryis. The FMX314, which received both CE Mark Approval and 510(k) Clearance last quarter, will be formally launched in the U.S. during the American College of Surgeons (ACS) Clinical Congress, taking place October 16 – 20, 2016 in Washington, D.C., where Fortimedix Surgical will be located at booth #1139. The European commercial launch is planned for 2017.
The company also has a subsidiary in San Diego.